Parand Darou Pharma Parand Darou Pharma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"QUANTRO Therapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$544.0 million","upfrontCash":"Undisclosed","newsHeadline":"QUANTRO Therapeutics reaches a milestone in the collaboration with Boehringer Ingelheim to develop first-in-class cancer treatments","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"AUSTRIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform"}]

    Find Clinical Drug Pipeline Developments & Deals by QUANTRO Therapeutics

    Menu

    QUANTRO Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              QUANTRO Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Austria
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              QUANTRO Therapeutics reaches a milestone in the collaboration with Boehringer Ingelheim to develop first-in-class cancer treatments

              Details:

              The collaboration is employing QUANTRO’s drug discovery platform based on time-resolved transcriptomics to identify drug candidates interfering with key transcriptional programs in cancer.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Small molecule

              Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH

              Deal Size: $544.0 million Upfront Cash: Undisclosed

              Deal Type: Collaboration June 04, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.
              IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.
              Post Enquiry
              POST ENQUIRY